СОВРЕМЕННЫЕ ЛЕЧЕБНО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ ПЕРВИЧНЫХ ЦЕФАЛГИЙ ПО НОВОЙ МЕЖДУНАРОДНОЙ КЛАССИФИКАЦИИ ГОЛОВНОЙ БОЛИ – ТРЕТЬЯ РЕДАКЦИЯ (2018)
Аннотация
В данной статье рассмотрены основные изменения, внесенные в обновленную международную классификацию головной боли третьего пересмотра (МКГБ-3, 2018). Определены актуальные лечебно-диагностические направления цефалгий с учетом патогенетических механизмов их развития.
Литература
1. Осипова В.В. Первичные головные боли: диагностика и лечение. Методические рекомендации. М.; 2017. 27.
2. Шнайдер Н.А., Кондратьев А.В., Шнайдер Н.А., Шульмин А.В. Эпидемиология головных болей. Современные проблемы науки и образования. 2015; 6. URL: http://science-education.ru/ru/article/view?id=22811 (дата обращения: 11.11.2019).
3. American Headache Society (2019) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019; 59(1): 1–18.
4. Headache Clasification Subcommittee of the IHS. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1):1-211.
5. Колбин А.С., Наприенко М.В., Артеменко А.Р., Вилюм И.А., Латышева Н.В., Проскурин М.А., Балыкина Ю.Е. Социально-экономическое бремя хронической мигрени в России. Качественная клиническая практика. 2018; 3: 26-44. DOI: 10.24411/2588-0519-2018-10049.
6. Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen, Lars Bendtsen. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2019; 39(7): 863-72.
7. Осипова В.В., Табеева Г.Р. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. М.: Медицинское информационное агентство; 2014. 336.
8. Гиниатуллин Р.А. Нейрофизиологические механизмы мигрени и новые принципы патогенетического лечения. Казанский медицинский журнал. 2011; 92 (5): 728-735.
9. Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of Migraine – a disorder of sensory processing. Comprehensive review of migraine pathophysiology. Physiol Rev. 2017; 97: 553–622.
10. Pietrobon D., Moskowitz M.A. Pathophysiology of migraine. Annu Rev Physiol. 2013; 75: 365–91.
11. Филатова Е.Г., Амелин А.В., Табеева Г.Р. Ready – первое российское мультицентровое исследование эффективности препарата релпакс (элетриптан) при лечении мигрени. Лечение нервных болезней. 2006; 2: 19–22.
12. Hershey A.D. CGRP - the next frontier formigraine. N Engl J Med. 2017; 377(22): 2190-91. doi: 10.1056/NEJMe1712559.
13. Hougaard A., Hauge A., Guo S., Tfelt-Hansen P. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Scan J Pain. 2012; 4: 48–52.
14. Тадтаева З. Г. Генетика мигрени. Вестник Санкт-Петербургского университета. 2013: 1: 70-80.
15. Кондратьева Н.С. Поиск молекулярно-генетических основ патогенеза мигрени: дис. Москва; 2016. 167.
16. Строгонова В. В., Мальцева А. С. Генетические предикторы мигрени. The Journal of scientific articles “Health and Education Millennium”. 2017; 19 (3): 105-107.
17. Osipova V., Jensen R., Tassorelli C. The use of diaries in the management of headache. Handbook of Headache (Practical Management). Eds. P. Martelletti, T.J. Steiner. 2011; 4: 197–209.
18. Alder announces eptinezumab significantly reduces migraine risk meets primary and all key secondary endpoints in pivotal PROMISE 2 phase 3 trial for chronic migraine prevention [news release]. Bothell, WA: Globe Newswire/Alder BioPharmaceuticals Inc. January 8, 2018. globenewswire.com/news-release/2018/01/08/1284947/0/en/Alder-Announces-Eptinezumab-Significantly-Reduces-Migraine-Risk-Meets-Primary-and-All-Key-Secondary-Endpoints-in-Pivotal-PROMISE-2-Phase-3-Trial-for-Chronic-Migraine-Prevention.html. Accessed April 10, 2018.
19. Азимова Ю.Э., Рачин А.П., Ищенко К.А., Данилов А.Б. Инновационные методы лечения мигрени. РМЖ. Болевой синдром. 2015; 27–30.
20. Dodick D.W., Goadsby P.J., Spierings E.L.H., Scherer J.C., Sweeney S.P., Grayzel D.S. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014;13: 885–92.
21. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014; 94 (4): 1099–142.
22. MaassenVan Den Brink A., Meijer J., Villalon C.M., Ferrari M.D. Wiping out CGRP: potential cardiovascular risks. Summary of cardiovascular and cerebrovascular effects of CGRP. Trends Pharmacol Sci. 2016; 37(9): 779–88.
23. Edvinsson L. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev. 2005;11 (1): 69-76.
24. Voss T., Lipton R.B., Dodick D.W., Dupre N., Ge J.Y., Bachman R., et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016; 36: 887–98.
25. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology (Minneap). 2014; 83: 958–66.
26. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. A randomised, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. Lancet Neurol. 2016; 15: 382–90.
27. Goadsby P.J., Reuter U., Hallström Y., et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017; 377 (22): 2123-32. doi: 10.1056/NEJMoa1705848.
28. Lipton R.B., Brennan A., Palmer S., et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018; 3:1-26. doi: 10.1080/13696998.2018.1457533.
29. Головачева В.А., Парфенов В.А. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Невролог. журн. 2015; 3(20): 37–43
30. Hepp Z., Dodick D.W., Varon S.F., Gillard P., Hansen R.N., Devine E.B. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; 35(6): 478–88.
31. Zhu S., Marmura M.J. Non-Invasive Neuromodulation for Headache Disorders // Current Neurology Neuroscience Reports. 2016. 16(2): 11.
32. Becker W.J. Acute Migraine Treatment in Adults. Headache. 2015; 55: 778–93.
33. Wrobel Goldberg S., Silberstein S.D. Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs. 2015; 29 (6): 443–52.
34. Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(8): 27. ncbi.nlm.nih.gov/pmc/articles/PMC5486583.
35. Dominquez C, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018; 25(2): 411-16. DOI: 10.1111/ene.13523
36. Bigal M.E., Dodick D.W., Krymchantowski A.V., Vander Pluym J.H., Tepper S.J., Aycardi E., et al. TEV-48125 for the preventive treatment of chronic migraine-efficacy at early time points. Neurology (Minneap). 2016; 87: 41–8.
37. Bigal M.E., Dodick D.W., Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14: 1081–90.
38. Bigal M.E., Edvinsson L., Rapoport A.M., Lipton R.B., Spierings E.L.H., Diener H. C., et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14: 1091–100.
39. Silberstein S.D., Dodick D.W., Bigal M.E., et al. Fremanezumab for the preventive treatment ofchronic migraine. N Engl J Med. 2017; 377(22): 2113-22. doi: 10.1056/NEJMoa1709038.
40. Sklijarevski V., Oakes T.M., Zhan Q., et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018; 75(2): 187-93. doi: 10.1001/jamaneurol.2017.3859.
41. Lilly’s galcanezumab significantly reduces number of migraine headache days for patients with migraine: new results presented at AHS [news release]. Indianapolis, IN: PRNewswire/Eli Lilly and Co; June 10, 2017. URL: prnewswire.com/news-releases/lillys-galcanezumab-significantly-reduces-number-of-migraine-headache-days-for-patients-with-migraine-new-results-presented-at-ahs-300471742.html. (Accessed April 10, 2018).
42. Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018; 38(10): 1622-31. doi: 10.1177/0333102418789072.
43. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017; 377(22): 2123-32. doi: 10.1056/NEJMoa1705848.
44. Sunfa Cheng, Herman Picard, Feng Zhang, Osa Eisele, Daniel Mikol. Efficacy and safety of erenumab for migraine prevention: an overview. Japanese Journal of Headache. 2019; 45(3): 493-505.
45. Pellesi L., Guerzoni S., Pini L.A. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017; 6(6): 534-47. doi: 10.1002/cpdd.345.
46. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Comprehensive review of CGRP pharmacology. Br J Clin Pharmacol. 2015; 80:193–9.
47. Färkkilä M., Diener H.C., Géraud G. et al. and the COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study // Lancet Neurol. 2012; 11: 405–13.
48. Ferrari M.D., Färkkilä M., Reuter U. et al. and the European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170–8.
49. Gomez-Mancilla B., Brand R., Jürgens T.P. et al. and the BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014; 34: 103–113.
50. Chizh B.A., O’Donnell M.B., Napolitano A. et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain. 2007; 132: 132–141.
51. Agneta Snoer, Anne Luise H. Vollesen, Rasmus P. Beske, Song Guo, Jan Hoffmann,Jan Fahrenkrug, Niklas Rye Jørgensen, Torben Martinussen, Rigmor H Jensen, Messoud Ashina. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019; 39(5): 575-84.
52. Pernille Linde Jellestad, Louise Ninett Carlsen, Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Miguel Lainez, Ricardo Fadic, Zaza Katsarava, Maria Teresa Goicochea, Santiago Spadafora, Rigmor Højland Jensen, Giuseppe Nappi, Cristina Tassorelli. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project. Cephalalgia. 2019; 39(2):274-85.
2. Шнайдер Н.А., Кондратьев А.В., Шнайдер Н.А., Шульмин А.В. Эпидемиология головных болей. Современные проблемы науки и образования. 2015; 6. URL: http://science-education.ru/ru/article/view?id=22811 (дата обращения: 11.11.2019).
3. American Headache Society (2019) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019; 59(1): 1–18.
4. Headache Clasification Subcommittee of the IHS. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1):1-211.
5. Колбин А.С., Наприенко М.В., Артеменко А.Р., Вилюм И.А., Латышева Н.В., Проскурин М.А., Балыкина Ю.Е. Социально-экономическое бремя хронической мигрени в России. Качественная клиническая практика. 2018; 3: 26-44. DOI: 10.24411/2588-0519-2018-10049.
6. Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen, Lars Bendtsen. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2019; 39(7): 863-72.
7. Осипова В.В., Табеева Г.Р. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. М.: Медицинское информационное агентство; 2014. 336.
8. Гиниатуллин Р.А. Нейрофизиологические механизмы мигрени и новые принципы патогенетического лечения. Казанский медицинский журнал. 2011; 92 (5): 728-735.
9. Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of Migraine – a disorder of sensory processing. Comprehensive review of migraine pathophysiology. Physiol Rev. 2017; 97: 553–622.
10. Pietrobon D., Moskowitz M.A. Pathophysiology of migraine. Annu Rev Physiol. 2013; 75: 365–91.
11. Филатова Е.Г., Амелин А.В., Табеева Г.Р. Ready – первое российское мультицентровое исследование эффективности препарата релпакс (элетриптан) при лечении мигрени. Лечение нервных болезней. 2006; 2: 19–22.
12. Hershey A.D. CGRP - the next frontier formigraine. N Engl J Med. 2017; 377(22): 2190-91. doi: 10.1056/NEJMe1712559.
13. Hougaard A., Hauge A., Guo S., Tfelt-Hansen P. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Scan J Pain. 2012; 4: 48–52.
14. Тадтаева З. Г. Генетика мигрени. Вестник Санкт-Петербургского университета. 2013: 1: 70-80.
15. Кондратьева Н.С. Поиск молекулярно-генетических основ патогенеза мигрени: дис. Москва; 2016. 167.
16. Строгонова В. В., Мальцева А. С. Генетические предикторы мигрени. The Journal of scientific articles “Health and Education Millennium”. 2017; 19 (3): 105-107.
17. Osipova V., Jensen R., Tassorelli C. The use of diaries in the management of headache. Handbook of Headache (Practical Management). Eds. P. Martelletti, T.J. Steiner. 2011; 4: 197–209.
18. Alder announces eptinezumab significantly reduces migraine risk meets primary and all key secondary endpoints in pivotal PROMISE 2 phase 3 trial for chronic migraine prevention [news release]. Bothell, WA: Globe Newswire/Alder BioPharmaceuticals Inc. January 8, 2018. globenewswire.com/news-release/2018/01/08/1284947/0/en/Alder-Announces-Eptinezumab-Significantly-Reduces-Migraine-Risk-Meets-Primary-and-All-Key-Secondary-Endpoints-in-Pivotal-PROMISE-2-Phase-3-Trial-for-Chronic-Migraine-Prevention.html. Accessed April 10, 2018.
19. Азимова Ю.Э., Рачин А.П., Ищенко К.А., Данилов А.Б. Инновационные методы лечения мигрени. РМЖ. Болевой синдром. 2015; 27–30.
20. Dodick D.W., Goadsby P.J., Spierings E.L.H., Scherer J.C., Sweeney S.P., Grayzel D.S. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014;13: 885–92.
21. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014; 94 (4): 1099–142.
22. MaassenVan Den Brink A., Meijer J., Villalon C.M., Ferrari M.D. Wiping out CGRP: potential cardiovascular risks. Summary of cardiovascular and cerebrovascular effects of CGRP. Trends Pharmacol Sci. 2016; 37(9): 779–88.
23. Edvinsson L. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev. 2005;11 (1): 69-76.
24. Voss T., Lipton R.B., Dodick D.W., Dupre N., Ge J.Y., Bachman R., et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016; 36: 887–98.
25. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology (Minneap). 2014; 83: 958–66.
26. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. A randomised, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. Lancet Neurol. 2016; 15: 382–90.
27. Goadsby P.J., Reuter U., Hallström Y., et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017; 377 (22): 2123-32. doi: 10.1056/NEJMoa1705848.
28. Lipton R.B., Brennan A., Palmer S., et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018; 3:1-26. doi: 10.1080/13696998.2018.1457533.
29. Головачева В.А., Парфенов В.А. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Невролог. журн. 2015; 3(20): 37–43
30. Hepp Z., Dodick D.W., Varon S.F., Gillard P., Hansen R.N., Devine E.B. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; 35(6): 478–88.
31. Zhu S., Marmura M.J. Non-Invasive Neuromodulation for Headache Disorders // Current Neurology Neuroscience Reports. 2016. 16(2): 11.
32. Becker W.J. Acute Migraine Treatment in Adults. Headache. 2015; 55: 778–93.
33. Wrobel Goldberg S., Silberstein S.D. Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs. 2015; 29 (6): 443–52.
34. Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(8): 27. ncbi.nlm.nih.gov/pmc/articles/PMC5486583.
35. Dominquez C, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018; 25(2): 411-16. DOI: 10.1111/ene.13523
36. Bigal M.E., Dodick D.W., Krymchantowski A.V., Vander Pluym J.H., Tepper S.J., Aycardi E., et al. TEV-48125 for the preventive treatment of chronic migraine-efficacy at early time points. Neurology (Minneap). 2016; 87: 41–8.
37. Bigal M.E., Dodick D.W., Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14: 1081–90.
38. Bigal M.E., Edvinsson L., Rapoport A.M., Lipton R.B., Spierings E.L.H., Diener H. C., et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14: 1091–100.
39. Silberstein S.D., Dodick D.W., Bigal M.E., et al. Fremanezumab for the preventive treatment ofchronic migraine. N Engl J Med. 2017; 377(22): 2113-22. doi: 10.1056/NEJMoa1709038.
40. Sklijarevski V., Oakes T.M., Zhan Q., et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018; 75(2): 187-93. doi: 10.1001/jamaneurol.2017.3859.
41. Lilly’s galcanezumab significantly reduces number of migraine headache days for patients with migraine: new results presented at AHS [news release]. Indianapolis, IN: PRNewswire/Eli Lilly and Co; June 10, 2017. URL: prnewswire.com/news-releases/lillys-galcanezumab-significantly-reduces-number-of-migraine-headache-days-for-patients-with-migraine-new-results-presented-at-ahs-300471742.html. (Accessed April 10, 2018).
42. Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018; 38(10): 1622-31. doi: 10.1177/0333102418789072.
43. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017; 377(22): 2123-32. doi: 10.1056/NEJMoa1705848.
44. Sunfa Cheng, Herman Picard, Feng Zhang, Osa Eisele, Daniel Mikol. Efficacy and safety of erenumab for migraine prevention: an overview. Japanese Journal of Headache. 2019; 45(3): 493-505.
45. Pellesi L., Guerzoni S., Pini L.A. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017; 6(6): 534-47. doi: 10.1002/cpdd.345.
46. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Comprehensive review of CGRP pharmacology. Br J Clin Pharmacol. 2015; 80:193–9.
47. Färkkilä M., Diener H.C., Géraud G. et al. and the COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study // Lancet Neurol. 2012; 11: 405–13.
48. Ferrari M.D., Färkkilä M., Reuter U. et al. and the European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170–8.
49. Gomez-Mancilla B., Brand R., Jürgens T.P. et al. and the BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014; 34: 103–113.
50. Chizh B.A., O’Donnell M.B., Napolitano A. et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain. 2007; 132: 132–141.
51. Agneta Snoer, Anne Luise H. Vollesen, Rasmus P. Beske, Song Guo, Jan Hoffmann,Jan Fahrenkrug, Niklas Rye Jørgensen, Torben Martinussen, Rigmor H Jensen, Messoud Ashina. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019; 39(5): 575-84.
52. Pernille Linde Jellestad, Louise Ninett Carlsen, Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Miguel Lainez, Ricardo Fadic, Zaza Katsarava, Maria Teresa Goicochea, Santiago Spadafora, Rigmor Højland Jensen, Giuseppe Nappi, Cristina Tassorelli. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project. Cephalalgia. 2019; 39(2):274-85.
Опубликована
2020-02-28
Как цитировать
КОЦЕНКО, Ю. И. et al.
СОВРЕМЕННЫЕ ЛЕЧЕБНО-ДИАГНОСТИЧЕСКИЕ ОСОБЕННОСТИ ПЕРВИЧНЫХ ЦЕФАЛГИЙ ПО НОВОЙ МЕЖДУНАРОДНОЙ КЛАССИФИКАЦИИ ГОЛОВНОЙ БОЛИ – ТРЕТЬЯ РЕДАКЦИЯ (2018).
Университетская клиника, [S.l.], n. 1(34), p. 62-73, фев. 2020.
ISSN 1819-0464. Доступно на: <http://journal.dnmu.ru/index.php/UC/article/view/387>. Дата доступа: 22 дек. 2024
doi: https://doi.org/10.26435/uc.v0i1(34).387.
Раздел
Обзоры
